Pharmacokinetic studies of linezolid and teicoplanin in the critically ill

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 3, 2005, Pages 333-340

  Whitehouse, Tony ^a   Cepeda, Jorge A ^b   Shulman, Rob ^b   Aarons, Leon ^c   Nalda Molina, Ricardo ^d   Tobin, Caroline ^e   MacGowan, Alasdair ^e   Shaw, Steve ^f   Kibbler, Chris ^f   Singer, Mervyn ^a   Wilson, A Peter R ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

^e SOUTHMEAD HOSPITAL   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

AUC; Critical care; HPLC; Pharmacokinetics

Indexed keywords

LINEZOLID; TEICOPLANIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; EMPYEMA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PANCREAS ABSCESS; PERITONITIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; URINARY TRACT INFECTION; WOUND INFECTION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXAZOLIDINONES; PROSPECTIVE STUDIES; TEICOPLANIN;

EID: 20144385743     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki014     Document Type: Article

References (37)

1. Swaney, S. M., Aoki, H., Ganoza, M. C. et al. (1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrobial Agents and Chemotherapy 42, 3251-5.
2. Champney, W. S. & Miller, M. (2002). Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Current Microbiology 44, 350-6.
3. Dresser, L. D. & Rybak, M. J. (1998). The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456-62,
4. Rayner, C. R., Forrest, A., Meagher, A. K., et al. (2000). Population pharmacodynamics; of linezolid in seriously ill adult patients from a compassionate use protocol. In Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 1390, p. 29. American Society for Microbiology, Washington, DC, USA.
5. Meagher, A. K., Forrest, A., Rayner, C. R. et al. (2003). Population pharmacokinetics of linezolid in patients treated in a compassionate-use program, Antimicrobial Agents and Chemotherapy 47, 548-53.
6. Stalker, D. & Jungbluth, G. (2003). Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clinical Pharmacokinetics 42, 1129-40.
7. Brier, M. E., Stalker, D. J., Aronoff, G. R. et al. (2003). Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrobial Agents and Chemotherapy 47, 2775-80.
8. Bowker, K. E., Wootton, M., Holt, H. A. et al. (2002). In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. Journal of Antimicrobial Chemotherapy 49, 578-80.
9. Gee, T., Ellis, R., Marshall, G. et al. (2001). Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrobial Agents and Chemotherapy 45, 1843-6.
10. Slatter, J. G., Stalker, D. J., Feenstra, K. L. et al. (2001). Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metabolism and Disposition 29, 1136-45.
11. de Mendonca, A., Vincent, J. L., Suter, P. M. et al. (2000). Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Medicine 26, 915-21.
12. Humphrey, S. J., Curry, J. T., Turman, C. N. et al. (2001). Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. Journal of Cardiovascular Pharmacology 37, 548-63.
13. Wilson, A. P. (2000). Clinical pharmacokinetics of teicoplanin. Clinical Pharmacokinetics 39, 167-83.
14. Traina, G. L. & Bonati, M. (1984). Pharmacokinetics of teicoplanin in man after intravenous administration. Journal of Pharmacokinetics and Biopharmaceutics 12, 119-28.
15. Reynolds, R., Potz, N., Colman, M. et al. (2004). Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy 53, 1018-32.
16. MacGowan, A. P. & Wise, R. (2001). Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy 48, Suppl. 1 17-28.
17. Bolmstrom, A., Ballow, C. H., Qwarnstrom, A. et al. (2002). Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clinical Microbiology and Infection 8, 791-800.
18. Craig, W. A. (2003). Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infectious Disease Clinics of North America 17, 479-501.
19. Andes, D., van Ogtrop, M. L., Peng, J. et al. (2002). In vivo pharmacodynamics of a new oxazolidinone (linezolid), Antimicrobial Agents and Chemotherapy 46, 3484-9.
20. Craig, W. A. (2002). Pharmacodynamics of antimicrobials. General Concepts and applications. In Antimicrobial Pharmacodynamics in Theory and Clinical Practice, (Nightingale, C. H., Murakowa, T. & Ambrose, P. G. Eds), pp. 1-22. Marcel Dekker, Basel, Switzerland.
21. Cepeda, J. A., Whitehouse, T., Cooper, B. et al. (2004). Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. Journal of Antimicrobial Chemotherapy 53, 345-55.
22. Cockcroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
23. Tobin, C. M., Sunderland, J., White, L.. O. et al. (2001). A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. Journal of Antimicrobial Chemotherapy 48, 605-8.
24. Rybak, M. J., Bailey, E. M. & Reddy, V. N. (1991). Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrobial Agents and Chemotherapy 35, 1586-90.
25. Boeckmann, A. J., Sheiner, L. B. & Beal, S. L. (1994). NONMEM Users Guide. University of California, San Francisco, USA.
26. BSAC. (2003). BSAC Resistance Surveillance website. Bacteraemia. [Online.] http://www.bsacsurv.org (22 June 2004, date last accessed).
27. Harding, I., MacGowan, A. P., White, L. O. et al. (2000). Telcoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. Journal of Antimicrobial Chemotherapy 45, 835-41.
28. Stalker, D. J., Jungbluth, G. L., Hopkins, N. K. et al. (2003). Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. Journal of Antimicrobial Chemotherapy 51, 1239-46.
29. Sisson, T. L., Jungbluth, G. L. & Hopkins, N. K. (1999). A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. Journal of Clinical Pharmacology 39, 1277-82.
30. Fung, H. B., Kirschenbaum, H. L. & Ojofeitimi, B. O. (2001). Linezolid: an oxazolidinone antimicrobial agent. Clinical Therapeutics 23, 356-91.
31. Meyer, B., Kornek G, Nikfardjam, M. et al. (2004). Pharmacokinetics of linezolid in critically ill patients undergoing continuous venovenous hemofiltration. In Programs and Abstracts of the Twenty-fourth International Symposium on intensive Care and Emergency Medicine, Brussels, Belgium, 2004. Critical Care 8, Suppl. 1 113, Abstract P231.
32. Johnson, A. P., Henwood, C., Mushtaq, S. et al. (2003). Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. Journal of Hospital Infection 54, 179-87.
33. MacGowan, A. P. (2003). Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. Journal of Antimicrobial Chemotherapy 51, Suppl. 2, ii17-ii25.
34. Charbonneau, P., Harding, I., Garaud, J. J. et al. (1994). Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Medicine 20, Suppl. 4, S35-S42.
35. Pea, F., Brollo, L., Viale, P. et al. (2003). Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. Journal of Antimicrobial Chemotherapy 51, 971-5.
36. Pea, F., Viale, P., Candoni, A. et al. (2004). Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clinical Pharmacokinetics 43, 405-15.
37. Darley, E. S. & MacGowan, A. P. (2004). Antibiotic treatment of Gram-positive bone and joint infections. Journal of Antimicrobial Chemotherapy 53, 928-35.